Abstract
Background. Allergic rhinitis (AR) is the most prevalent allergic disease globally, particularly within the pediatric population. Its high prevalence and substantial impact on quality of life render it a pressing clinical concern. Notable challenges persist in early diagnosis, comprehension of pathogenetic mechanisms, and optimization of therapeutic strategies, especially in young children. Objective. To present a contemporary review and consensus recommendations from the Association of Pediatric Allergists and Immunologists of Russia (APAIR) on the management of pediatric AR, encompassing pathogenetic mechanisms, risk factors, clinical presentation, diagnostic approaches, and therapeutic modalities. Materials and Methods. This work synthesizes current national and international research, including data from meta-analyses and clinical guidelines, alongside original expert contributions from APAIR members. Results. Experts conceptualize AR as a mixed immune-inflammatory disorder involving the classical IgE-dependent pathway (Type I), cellular responses (Type IV), and epithelial dysfunction (Type V). The significance of risk factors, including genetics, microbiome composition, pollutant exposure, and allergen contact, is underscored. Data on the substantial prevalence of AR are presented, highlighting its underdiagnosis in young children and patients with comorbid conditions such as atopic dermatitis and food allergy. A refined, more clinically applicable definition of AR is proposed. Algorithms for stepwise pharmacotherapy are thoroughly detailed, including the evidence-based use of antihistamines as initial therapy for young children and patients with mild AR, intranasal corticosteroids as the cornerstone of treatment, and fixed intranasal combinations for both baseline and on-demand therapy. A personalized approach based on age (0–18 years) and clinical phenotype is emphasized. APAIR experts underscore the role of allergen-specific immunotherapy (AIT) as the only disease-modifying intervention, in contrast to pharmacotherapy, which primarily provides symptomatic control. Conclusion. Timely diagnosis and appropriate, stepwise therapy for AR in children facilitate symptom control and significantly improve patients’ quality of life. Furthermore, the incorporation of AIT can prevent disease progression, including the development of bronchial asthma. This consensus document aims to assist clinicians in making evidence-based clinical decisions.

This publication has 510 references indexed in Scilit: